1 Study Coverage
    1.1 Conjugate Vaccines Product Introduction
    1.2 Market by Type
        1.2.1 Global Conjugate Vaccines Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Monovalent Conjugate Vaccines
        1.2.3 Multivalent Conjugate Vaccines
    1.3 Market by Application
        1.3.1 Global Conjugate Vaccines Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Children
        1.3.3 Adults
    1.4 Study Objectives
    1.5 Years Considered
2 Executive Summary
    2.1 Global Conjugate Vaccines Sales Estimates and Forecasts 2017-2028
    2.2 Global Conjugate Vaccines Revenue Estimates and Forecasts 2017-2028
    2.3 Global Conjugate Vaccines Revenue by Region: 2017 VS 2021 VS 2028
    2.4 Global Conjugate Vaccines Sales by Region
        2.4.1 Global Conjugate Vaccines Sales by Region (2017-2022)
        2.4.2 Global Sales Conjugate Vaccines by Region (2023-2028)
    2.5 Global Conjugate Vaccines Revenue by Region
        2.5.1 Global Conjugate Vaccines Revenue by Region (2017-2022)
        2.5.2 Global Conjugate Vaccines Revenue by Region (2023-2028)
    2.6 North America
    2.7 Europe
    2.8 Asia-Pacific
    2.9 Latin America
    2.10 Middle East & Africa
3 Competition by Manufacturers
    3.1 Global Conjugate Vaccines Sales by Manufacturers
        3.1.1 Global Top Conjugate Vaccines Manufacturers by Sales (2017-2022)
        3.1.2 Global Conjugate Vaccines Sales Market Share by Manufacturers (2017-2022)
        3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Conjugate Vaccines in 2021
    3.2 Global Conjugate Vaccines Revenue by Manufacturers
        3.2.1 Global Conjugate Vaccines Revenue by Manufacturers (2017-2022)
        3.2.2 Global Conjugate Vaccines Revenue Market Share by Manufacturers (2017-2022)
        3.2.3 Global Top 10 and Top 5 Companies by Conjugate Vaccines Revenue in 2021
    3.3 Global Conjugate Vaccines Sales Price by Manufacturers (2017-2022)
    3.4 Analysis of Competitive Landscape
        3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Conjugate Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
        3.4.3 Global Conjugate Vaccines Manufacturers Geographical Distribution
    3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
    4.1 Global Conjugate Vaccines Sales by Type
        4.1.1 Global Conjugate Vaccines Historical Sales by Type (2017-2022)
        4.1.2 Global Conjugate Vaccines Forecasted Sales by Type (2023-2028)
        4.1.3 Global Conjugate Vaccines Sales Market Share by Type (2017-2028)
    4.2 Global Conjugate Vaccines Revenue by Type
        4.2.1 Global Conjugate Vaccines Historical Revenue by Type (2017-2022)
        4.2.2 Global Conjugate Vaccines Forecasted Revenue by Type (2023-2028)
        4.2.3 Global Conjugate Vaccines Revenue Market Share by Type (2017-2028)
    4.3 Global Conjugate Vaccines Price by Type
        4.3.1 Global Conjugate Vaccines Price by Type (2017-2022)
        4.3.2 Global Conjugate Vaccines Price Forecast by Type (2023-2028)
5 Market Size by Application
    5.1 Global Conjugate Vaccines Sales by Application
        5.1.1 Global Conjugate Vaccines Historical Sales by Application (2017-2022)
        5.1.2 Global Conjugate Vaccines Forecasted Sales by Application (2023-2028)
        5.1.3 Global Conjugate Vaccines Sales Market Share by Application (2017-2028)
    5.2 Global Conjugate Vaccines Revenue by Application
        5.2.1 Global Conjugate Vaccines Historical Revenue by Application (2017-2022)
        5.2.2 Global Conjugate Vaccines Forecasted Revenue by Application (2023-2028)
        5.2.3 Global Conjugate Vaccines Revenue Market Share by Application (2017-2028)
    5.3 Global Conjugate Vaccines Price by Application
        5.3.1 Global Conjugate Vaccines Price by Application (2017-2022)
        5.3.2 Global Conjugate Vaccines Price Forecast by Application (2023-2028)
6 North America
    6.1 North America Conjugate Vaccines Market Size by Type
        6.1.1 North America Conjugate Vaccines Sales by Type (2017-2028)
        6.1.2 North America Conjugate Vaccines Revenue by Type (2017-2028)
    6.2 North America Conjugate Vaccines Market Size by Application
        6.2.1 North America Conjugate Vaccines Sales by Application (2017-2028)
        6.2.2 North America Conjugate Vaccines Revenue by Application (2017-2028)
    6.3 North America Conjugate Vaccines Market Size by Country
        6.3.1 North America Conjugate Vaccines Sales by Country (2017-2028)
        6.3.2 North America Conjugate Vaccines Revenue by Country (2017-2028)
        6.3.3 U.S.
        6.3.4 Canada
7 Europe
    7.1 Europe Conjugate Vaccines Market Size by Type
        7.1.1 Europe Conjugate Vaccines Sales by Type (2017-2028)
        7.1.2 Europe Conjugate Vaccines Revenue by Type (2017-2028)
    7.2 Europe Conjugate Vaccines Market Size by Application
        7.2.1 Europe Conjugate Vaccines Sales by Application (2017-2028)
        7.2.2 Europe Conjugate Vaccines Revenue by Application (2017-2028)
    7.3 Europe Conjugate Vaccines Market Size by Country
        7.3.1 Europe Conjugate Vaccines Sales by Country (2017-2028)
        7.3.2 Europe Conjugate Vaccines Revenue by Country (2017-2028)
        7.3.3 Germany
        7.3.4 France
        7.3.5 U.K.
        7.3.6 Italy
        7.3.7 Russia
8 Asia Pacific
    8.1 Asia Pacific Conjugate Vaccines Market Size by Type
        8.1.1 Asia Pacific Conjugate Vaccines Sales by Type (2017-2028)
        8.1.2 Asia Pacific Conjugate Vaccines Revenue by Type (2017-2028)
    8.2 Asia Pacific Conjugate Vaccines Market Size by Application
        8.2.1 Asia Pacific Conjugate Vaccines Sales by Application (2017-2028)
        8.2.2 Asia Pacific Conjugate Vaccines Revenue by Application (2017-2028)
    8.3 Asia Pacific Conjugate Vaccines Market Size by Region
        8.3.1 Asia Pacific Conjugate Vaccines Sales by Region (2017-2028)
        8.3.2 Asia Pacific Conjugate Vaccines Revenue by Region (2017-2028)
        8.3.3 China
        8.3.4 Japan
        8.3.5 South Korea
        8.3.6 India
        8.3.7 Australia
        8.3.8 Taiwan
        8.3.9 Indonesia
        8.3.10 Thailand
        8.3.11 Malaysia
        8.3.12 Philippines
9 Latin America
    9.1 Latin America Conjugate Vaccines Market Size by Type
        9.1.1 Latin America Conjugate Vaccines Sales by Type (2017-2028)
        9.1.2 Latin America Conjugate Vaccines Revenue by Type (2017-2028)
    9.2 Latin America Conjugate Vaccines Market Size by Application
        9.2.1 Latin America Conjugate Vaccines Sales by Application (2017-2028)
        9.2.2 Latin America Conjugate Vaccines Revenue by Application (2017-2028)
    9.3 Latin America Conjugate Vaccines Market Size by Country
        9.3.1 Latin America Conjugate Vaccines Sales by Country (2017-2028)
        9.3.2 Latin America Conjugate Vaccines Revenue by Country (2017-2028)
        9.3.3 Mexico
        9.3.4 Brazil
        9.3.5 Argentina
10 Middle East and Africa
    10.1 Middle East and Africa Conjugate Vaccines Market Size by Type
        10.1.1 Middle East and Africa Conjugate Vaccines Sales by Type (2017-2028)
        10.1.2 Middle East and Africa Conjugate Vaccines Revenue by Type (2017-2028)
    10.2 Middle East and Africa Conjugate Vaccines Market Size by Application
        10.2.1 Middle East and Africa Conjugate Vaccines Sales by Application (2017-2028)
        10.2.2 Middle East and Africa Conjugate Vaccines Revenue by Application (2017-2028)
    10.3 Middle East and Africa Conjugate Vaccines Market Size by Country
        10.3.1 Middle East and Africa Conjugate Vaccines Sales by Country (2017-2028)
        10.3.2 Middle East and Africa Conjugate Vaccines Revenue by Country (2017-2028)
        10.3.3 Turkey
        10.3.4 Saudi Arabia
11 Company Profiles
    11.1 Novartis
        11.1.1 Novartis Corporation Information
        11.1.2 Novartis Overview
        11.1.3 Novartis Conjugate Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
        11.1.4 Novartis Conjugate Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
        11.1.5 Novartis Recent Developments
    11.2 Neuron Biotech
        11.2.1 Neuron Biotech Corporation Information
        11.2.2 Neuron Biotech Overview
        11.2.3 Neuron Biotech Conjugate Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
        11.2.4 Neuron Biotech Conjugate Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
        11.2.5 Neuron Biotech Recent Developments
    11.3 Serum Institute of India
        11.3.1 Serum Institute of India Corporation Information
        11.3.2 Serum Institute of India Overview
        11.3.3 Serum Institute of India Conjugate Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
        11.3.4 Serum Institute of India Conjugate Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
        11.3.5 Serum Institute of India Recent Developments
    11.4 Pfizer
        11.4.1 Pfizer Corporation Information
        11.4.2 Pfizer Overview
        11.4.3 Pfizer Conjugate Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
        11.4.4 Pfizer Conjugate Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
        11.4.5 Pfizer Recent Developments
    11.5 Sanofi Pasteur
        11.5.1 Sanofi Pasteur Corporation Information
        11.5.2 Sanofi Pasteur Overview
        11.5.3 Sanofi Pasteur Conjugate Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
        11.5.4 Sanofi Pasteur Conjugate Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
        11.5.5 Sanofi Pasteur Recent Developments
    11.6 Bharat Biotech
        11.6.1 Bharat Biotech Corporation Information
        11.6.2 Bharat Biotech Overview
        11.6.3 Bharat Biotech Conjugate Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
        11.6.4 Bharat Biotech Conjugate Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
        11.6.5 Bharat Biotech Recent Developments
    11.7 Biological
        11.7.1 Biological Corporation Information
        11.7.2 Biological Overview
        11.7.3 Biological Conjugate Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
        11.7.4 Biological Conjugate Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
        11.7.5 Biological Recent Developments
    11.8 GlaxoSmithKline
        11.8.1 GlaxoSmithKline Corporation Information
        11.8.2 GlaxoSmithKline Overview
        11.8.3 GlaxoSmithKline Conjugate Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
        11.8.4 GlaxoSmithKline Conjugate Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
        11.8.5 GlaxoSmithKline Recent Developments
    11.9 Merck
        11.9.1 Merck Corporation Information
        11.9.2 Merck Overview
        11.9.3 Merck Conjugate Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
        11.9.4 Merck Conjugate Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
        11.9.5 Merck Recent Developments
    11.10 CSL
        11.10.1 CSL Corporation Information
        11.10.2 CSL Overview
        11.10.3 CSL Conjugate Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
        11.10.4 CSL Conjugate Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
        11.10.5 CSL Recent Developments
12 Industry Chain and Sales Channels Analysis
    12.1 Conjugate Vaccines Industry Chain Analysis
    12.2 Conjugate Vaccines Key Raw Materials
        12.2.1 Key Raw Materials
        12.2.2 Raw Materials Key Suppliers
    12.3 Conjugate Vaccines Production Mode & Process
    12.4 Conjugate Vaccines Sales and Marketing
        12.4.1 Conjugate Vaccines Sales Channels
        12.4.2 Conjugate Vaccines Distributors
    12.5 Conjugate Vaccines Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
    13.1 Conjugate Vaccines Industry Trends
    13.2 Conjugate Vaccines Market Drivers
    13.3 Conjugate Vaccines Market Challenges
    13.4 Conjugate Vaccines Market Restraints
14 Key Findings in The Global Conjugate Vaccines Study
15 Appendix
    15.1 Research Methodology
        15.1.1 Methodology/Research Approach
        15.1.2 Data Source
    15.2 Author Details
    15.3 Disclaimer
                  
              

                

                 
List of Tables
    Table 1. Global Conjugate Vaccines Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
    Table 2. Major Manufacturers of Monovalent Conjugate Vaccines
    Table 3. Major Manufacturers of Multivalent Conjugate Vaccines
    Table 4. Global Conjugate Vaccines Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
    Table 5. Global Conjugate Vaccines Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
    Table 6. Global Conjugate Vaccines Sales by Region (2017-2022) & (K Doses)
    Table 7. Global Conjugate Vaccines Sales Market Share by Region (2017-2022)
    Table 8. Global Conjugate Vaccines Sales by Region (2023-2028) & (K Doses)
    Table 9. Global Conjugate Vaccines Sales Market Share by Region (2023-2028)
    Table 10. Global Conjugate Vaccines Revenue by Region (2017-2022) & (US$ Million)
    Table 11. Global Conjugate Vaccines Revenue Market Share by Region (2017-2022)
    Table 12. Global Conjugate Vaccines Revenue by Region (2023-2028) & (US$ Million)
    Table 13. Global Conjugate Vaccines Revenue Market Share by Region (2023-2028)
    Table 14. Global Conjugate Vaccines Sales by Manufacturers (2017-2022) & (K Doses)
    Table 15. Global Conjugate Vaccines Sales Share by Manufacturers (2017-2022)
    Table 16. Global Conjugate Vaccines Revenue by Manufacturers (2017-2022) & (US$ Million)
    Table 17. Global Conjugate Vaccines Revenue Share by Manufacturers (2017-2022)
    Table 18. Conjugate Vaccines Price by Manufacturers (2017-2022) &(USD/Doses)
    Table 19. Global Conjugate Vaccines Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 20. Global Conjugate Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Conjugate Vaccines as of 2021)
    Table 21. Conjugate Vaccines Manufacturing Base Distribution and Headquarters
    Table 22. Manufacturers Conjugate Vaccines Product Offered
    Table 23. Date of Manufacturers Enter into Conjugate Vaccines Market
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Conjugate Vaccines Sales by Type (2017-2022) & (K Doses)
    Table 26. Global Conjugate Vaccines Sales by Type (2023-2028) & (K Doses)
    Table 27. Global Conjugate Vaccines Sales Share by Type (2017-2022)
    Table 28. Global Conjugate Vaccines Sales Share by Type (2023-2028)
    Table 29. Global Conjugate Vaccines Revenue by Type (2017-2022) & (US$ Million)
    Table 30. Global Conjugate Vaccines Revenue by Type (2023-2028) & (US$ Million)
    Table 31. Global Conjugate Vaccines Revenue Share by Type (2017-2022)
    Table 32. Global Conjugate Vaccines Revenue Share by Type (2023-2028)
    Table 33. Conjugate Vaccines Price by Type (2017-2022) & (USD/Doses)
    Table 34. Global Conjugate Vaccines Price Forecast by Type (2023-2028) & (USD/Doses)
    Table 35. Global Conjugate Vaccines Sales by Application (2017-2022) & (K Doses)
    Table 36. Global Conjugate Vaccines Sales by Application (2023-2028) & (K Doses)
    Table 37. Global Conjugate Vaccines Sales Share by Application (2017-2022)
    Table 38. Global Conjugate Vaccines Sales Share by Application (2023-2028)
    Table 39. Global Conjugate Vaccines Revenue by Application (2017-2022) & (US$ Million)
    Table 40. Global Conjugate Vaccines Revenue by Application (2023-2028) & (US$ Million)
    Table 41. Global Conjugate Vaccines Revenue Share by Application (2017-2022)
    Table 42. Global Conjugate Vaccines Revenue Share by Application (2023-2028)
    Table 43. Conjugate Vaccines Price by Application (2017-2022) & (USD/Doses)
    Table 44. Global Conjugate Vaccines Price Forecast by Application (2023-2028) & (USD/Doses)
    Table 45. North America Conjugate Vaccines Sales by Type (2017-2022) & (K Doses)
    Table 46. North America Conjugate Vaccines Sales by Type (2023-2028) & (K Doses)
    Table 47. North America Conjugate Vaccines Revenue by Type (2017-2022) & (US$ Million)
    Table 48. North America Conjugate Vaccines Revenue by Type (2023-2028) & (US$ Million)
    Table 49. North America Conjugate Vaccines Sales by Application (2017-2022) & (K Doses)
    Table 50. North America Conjugate Vaccines Sales by Application (2023-2028) & (K Doses)
    Table 51. North America Conjugate Vaccines Revenue by Application (2017-2022) & (US$ Million)
    Table 52. North America Conjugate Vaccines Revenue by Application (2023-2028) & (US$ Million)
    Table 53. North America Conjugate Vaccines Sales by Country (2017-2022) & (K Doses)
    Table 54. North America Conjugate Vaccines Sales by Country (2023-2028) & (K Doses)
    Table 55. North America Conjugate Vaccines Revenue by Country (2017-2022) & (US$ Million)
    Table 56. North America Conjugate Vaccines Revenue by Country (2023-2028) & (US$ Million)
    Table 57. Europe Conjugate Vaccines Sales by Type (2017-2022) & (K Doses)
    Table 58. Europe Conjugate Vaccines Sales by Type (2023-2028) & (K Doses)
    Table 59. Europe Conjugate Vaccines Revenue by Type (2017-2022) & (US$ Million)
    Table 60. Europe Conjugate Vaccines Revenue by Type (2023-2028) & (US$ Million)
    Table 61. Europe Conjugate Vaccines Sales by Application (2017-2022) & (K Doses)
    Table 62. Europe Conjugate Vaccines Sales by Application (2023-2028) & (K Doses)
    Table 63. Europe Conjugate Vaccines Revenue by Application (2017-2022) & (US$ Million)
    Table 64. Europe Conjugate Vaccines Revenue by Application (2023-2028) & (US$ Million)
    Table 65. Europe Conjugate Vaccines Sales by Country (2017-2022) & (K Doses)
    Table 66. Europe Conjugate Vaccines Sales by Country (2023-2028) & (K Doses)
    Table 67. Europe Conjugate Vaccines Revenue by Country (2017-2022) & (US$ Million)
    Table 68. Europe Conjugate Vaccines Revenue by Country (2023-2028) & (US$ Million)
    Table 69. Asia Pacific Conjugate Vaccines Sales by Type (2017-2022) & (K Doses)
    Table 70. Asia Pacific Conjugate Vaccines Sales by Type (2023-2028) & (K Doses)
    Table 71. Asia Pacific Conjugate Vaccines Revenue by Type (2017-2022) & (US$ Million)
    Table 72. Asia Pacific Conjugate Vaccines Revenue by Type (2023-2028) & (US$ Million)
    Table 73. Asia Pacific Conjugate Vaccines Sales by Application (2017-2022) & (K Doses)
    Table 74. Asia Pacific Conjugate Vaccines Sales by Application (2023-2028) & (K Doses)
    Table 75. Asia Pacific Conjugate Vaccines Revenue by Application (2017-2022) & (US$ Million)
    Table 76. Asia Pacific Conjugate Vaccines Revenue by Application (2023-2028) & (US$ Million)
    Table 77. Asia Pacific Conjugate Vaccines Sales by Region (2017-2022) & (K Doses)
    Table 78. Asia Pacific Conjugate Vaccines Sales by Region (2023-2028) & (K Doses)
    Table 79. Asia Pacific Conjugate Vaccines Revenue by Region (2017-2022) & (US$ Million)
    Table 80. Asia Pacific Conjugate Vaccines Revenue by Region (2023-2028) & (US$ Million)
    Table 81. Latin America Conjugate Vaccines Sales by Type (2017-2022) & (K Doses)
    Table 82. Latin America Conjugate Vaccines Sales by Type (2023-2028) & (K Doses)
    Table 83. Latin America Conjugate Vaccines Revenue by Type (2017-2022) & (US$ Million)
    Table 84. Latin America Conjugate Vaccines Revenue by Type (2023-2028) & (US$ Million)
    Table 85. Latin America Conjugate Vaccines Sales by Application (2017-2022) & (K Doses)
    Table 86. Latin America Conjugate Vaccines Sales by Application (2023-2028) & (K Doses)
    Table 87. Latin America Conjugate Vaccines Revenue by Application (2017-2022) & (US$ Million)
    Table 88. Latin America Conjugate Vaccines Revenue by Application (2023-2028) & (US$ Million)
    Table 89. Latin America Conjugate Vaccines Sales by Country (2017-2022) & (K Doses)
    Table 90. Latin America Conjugate Vaccines Sales by Country (2023-2028) & (K Doses)
    Table 91. Latin America Conjugate Vaccines Revenue by Country (2017-2022) & (US$ Million)
    Table 92. Latin America Conjugate Vaccines Revenue by Country (2023-2028) & (US$ Million)
    Table 93. Middle East and Africa Conjugate Vaccines Sales by Type (2017-2022) & (K Doses)
    Table 94. Middle East and Africa Conjugate Vaccines Sales by Type (2023-2028) & (K Doses)
    Table 95. Middle East and Africa Conjugate Vaccines Revenue by Type (2017-2022) & (US$ Million)
    Table 96. Middle East and Africa Conjugate Vaccines Revenue by Type (2023-2028) & (US$ Million)
    Table 97. Middle East and Africa Conjugate Vaccines Sales by Application (2017-2022) & (K Doses)
    Table 98. Middle East and Africa Conjugate Vaccines Sales by Application (2023-2028) & (K Doses)
    Table 99. Middle East and Africa Conjugate Vaccines Revenue by Application (2017-2022) & (US$ Million)
    Table 100. Middle East and Africa Conjugate Vaccines Revenue by Application (2023-2028) & (US$ Million)
    Table 101. Middle East and Africa Conjugate Vaccines Sales by Country (2017-2022) & (K Doses)
    Table 102. Middle East and Africa Conjugate Vaccines Sales by Country (2023-2028) & (K Doses)
    Table 103. Middle East and Africa Conjugate Vaccines Revenue by Country (2017-2022) & (US$ Million)
    Table 104. Middle East and Africa Conjugate Vaccines Revenue by Country (2023-2028) & (US$ Million)
    Table 105. Novartis Corporation Information
    Table 106. Novartis Description and Major Businesses
    Table 107. Novartis Conjugate Vaccines Sales (K Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2017-2022)
    Table 108. Novartis Conjugate Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
    Table 109. Novartis Recent Developments
    Table 110. Neuron Biotech Corporation Information
    Table 111. Neuron Biotech Description and Major Businesses
    Table 112. Neuron Biotech Conjugate Vaccines Sales (K Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2017-2022)
    Table 113. Neuron Biotech Conjugate Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
    Table 114. Neuron Biotech Recent Developments
    Table 115. Serum Institute of India Corporation Information
    Table 116. Serum Institute of India Description and Major Businesses
    Table 117. Serum Institute of India Conjugate Vaccines Sales (K Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2017-2022)
    Table 118. Serum Institute of India Conjugate Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
    Table 119. Serum Institute of India Recent Developments
    Table 120. Pfizer Corporation Information
    Table 121. Pfizer Description and Major Businesses
    Table 122. Pfizer Conjugate Vaccines Sales (K Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2017-2022)
    Table 123. Pfizer Conjugate Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
    Table 124. Pfizer Recent Developments
    Table 125. Sanofi Pasteur Corporation Information
    Table 126. Sanofi Pasteur Description and Major Businesses
    Table 127. Sanofi Pasteur Conjugate Vaccines Sales (K Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2017-2022)
    Table 128. Sanofi Pasteur Conjugate Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
    Table 129. Sanofi Pasteur Recent Developments
    Table 130. Bharat Biotech Corporation Information
    Table 131. Bharat Biotech Description and Major Businesses
    Table 132. Bharat Biotech Conjugate Vaccines Sales (K Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2017-2022)
    Table 133. Bharat Biotech Conjugate Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
    Table 134. Bharat Biotech Recent Developments
    Table 135. Biological Corporation Information
    Table 136. Biological Description and Major Businesses
    Table 137. Biological Conjugate Vaccines Sales (K Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2017-2022)
    Table 138. Biological Conjugate Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
    Table 139. Biological Recent Developments
    Table 140. GlaxoSmithKline Corporation Information
    Table 141. GlaxoSmithKline Description and Major Businesses
    Table 142. GlaxoSmithKline Conjugate Vaccines Sales (K Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2017-2022)
    Table 143. GlaxoSmithKline Conjugate Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
    Table 144. GlaxoSmithKline Recent Developments
    Table 145. Merck Corporation Information
    Table 146. Merck Description and Major Businesses
    Table 147. Merck Conjugate Vaccines Sales (K Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2017-2022)
    Table 148. Merck Conjugate Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
    Table 149. Merck Recent Developments
    Table 150. CSL Corporation Information
    Table 151. CSL Description and Major Businesses
    Table 152. CSL Conjugate Vaccines Sales (K Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2017-2022)
    Table 153. CSL Conjugate Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
    Table 154. CSL Recent Developments
    Table 155. Key Raw Materials Lists
    Table 156. Raw Materials Key Suppliers Lists
    Table 157. Conjugate Vaccines Distributors List
    Table 158. Conjugate Vaccines Customers List
    Table 159. Conjugate Vaccines Market Trends
    Table 160. Conjugate Vaccines Market Drivers
    Table 161. Conjugate Vaccines Market Challenges
    Table 162. Conjugate Vaccines Market Restraints
    Table 163. Research Programs/Design for This Report
    Table 164. Key Data Information from Secondary Sources
    Table 165. Key Data Information from Primary Sources
List of Figures
    Figure 1. Conjugate Vaccines Product Picture
    Figure 3. Global Conjugate Vaccines Market Share by Type in 2021 & 2028
    Figure 3. Monovalent Conjugate Vaccines Product Picture
    Figure 4. Multivalent Conjugate Vaccines Product Picture
    Figure 5. Global Conjugate Vaccines Market Share by Application in 2021 & 2028
    Figure 6. Children
    Figure 7. Adults
    Figure 8. Conjugate Vaccines Report Years Considered
    Figure 9. Global Conjugate Vaccines Sales 2017-2028 (K Doses)
    Figure 10. Global Conjugate Vaccines Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 11. Global Conjugate Vaccines Revenue 2017-2028 (US$ Million)
    Figure 12. Global Conjugate Vaccines Revenue Market Share by Region in Percentage: 2021 Versus 2028
    Figure 13. Global Conjugate Vaccines Sales Market Share by Region (2017-2022)
    Figure 14. Global Conjugate Vaccines Sales Market Share by Region (2023-2028)
    Figure 15. North America Conjugate Vaccines Sales YoY (2017-2028) & (K Doses)
    Figure 16. North America Conjugate Vaccines Revenue YoY (2017-2028) & (US$ Million)
    Figure 17. Europe Conjugate Vaccines Sales YoY (2017-2028) & (K Doses)
    Figure 18. Europe Conjugate Vaccines Revenue YoY (2017-2028) & (US$ Million)
    Figure 19. Asia-Pacific Conjugate Vaccines Sales YoY (2017-2028) & (K Doses)
    Figure 20. Asia-Pacific Conjugate Vaccines Revenue YoY (2017-2028) & (US$ Million)
    Figure 21. Latin America Conjugate Vaccines Sales YoY (2017-2028) & (K Doses)
    Figure 22. Latin America Conjugate Vaccines Revenue YoY (2017-2028) & (US$ Million)
    Figure 23. Middle East & Africa Conjugate Vaccines Sales YoY (2017-2028) & (K Doses)
    Figure 24. Middle East & Africa Conjugate Vaccines Revenue YoY (2017-2028) & (US$ Million)
    Figure 25. The Conjugate Vaccines Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
    Figure 26. The Top 5 and 10 Largest Manufacturers of Conjugate Vaccines in the World: Market Share by Conjugate Vaccines Revenue in 2021
    Figure 27. Global Conjugate Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
    Figure 28. Global Conjugate Vaccines Sales Market Share by Type (2017-2028)
    Figure 29. Global Conjugate Vaccines Revenue Market Share by Type (2017-2028)
    Figure 30. Global Conjugate Vaccines Sales Market Share by Application (2017-2028)
    Figure 31. Global Conjugate Vaccines Revenue Market Share by Application (2017-2028)
    Figure 32. North America Conjugate Vaccines Sales Market Share by Type (2017-2028)
    Figure 33. North America Conjugate Vaccines Revenue Market Share by Type (2017-2028)
    Figure 34. North America Conjugate Vaccines Sales Market Share by Application (2017-2028)
    Figure 35. North America Conjugate Vaccines Revenue Market Share by Application (2017-2028)
    Figure 36. North America Conjugate Vaccines Sales Share by Country (2017-2028)
    Figure 37. North America Conjugate Vaccines Revenue Share by Country (2017-2028)
    Figure 38. U.S. Conjugate Vaccines Revenue (2017-2028) & (US$ Million)
    Figure 39. Canada Conjugate Vaccines Revenue (2017-2028) & (US$ Million)
    Figure 40. Europe Conjugate Vaccines Sales Market Share by Type (2017-2028)
    Figure 41. Europe Conjugate Vaccines Revenue Market Share by Type (2017-2028)
    Figure 42. Europe Conjugate Vaccines Sales Market Share by Application (2017-2028)
    Figure 43. Europe Conjugate Vaccines Revenue Market Share by Application (2017-2028)
    Figure 44. Europe Conjugate Vaccines Sales Share by Country (2017-2028)
    Figure 45. Europe Conjugate Vaccines Revenue Share by Country (2017-2028)
    Figure 46. Germany Conjugate Vaccines Revenue (2017-2028) & (US$ Million)
    Figure 47. France Conjugate Vaccines Revenue (2017-2028) & (US$ Million)
    Figure 48. U.K. Conjugate Vaccines Revenue (2017-2028) & (US$ Million)
    Figure 49. Italy Conjugate Vaccines Revenue (2017-2028) & (US$ Million)
    Figure 50. Russia Conjugate Vaccines Revenue (2017-2028) & (US$ Million)
    Figure 51. Asia Pacific Conjugate Vaccines Sales Market Share by Type (2017-2028)
    Figure 52. Asia Pacific Conjugate Vaccines Revenue Market Share by Type (2017-2028)
    Figure 53. Asia Pacific Conjugate Vaccines Sales Market Share by Application (2017-2028)
    Figure 54. Asia Pacific Conjugate Vaccines Revenue Market Share by Application (2017-2028)
    Figure 55. Asia Pacific Conjugate Vaccines Sales Share by Region (2017-2028)
    Figure 56. Asia Pacific Conjugate Vaccines Revenue Share by Region (2017-2028)
    Figure 57. China Conjugate Vaccines Revenue (2017-2028) & (US$ Million)
    Figure 58. Japan Conjugate Vaccines Revenue (2017-2028) & (US$ Million)
    Figure 59. South Korea Conjugate Vaccines Revenue (2017-2028) & (US$ Million)
    Figure 60. India Conjugate Vaccines Revenue (2017-2028) & (US$ Million)
    Figure 61. Australia Conjugate Vaccines Revenue (2017-2028) & (US$ Million)
    Figure 62. Taiwan Conjugate Vaccines Revenue (2017-2028) & (US$ Million)
    Figure 63. Indonesia Conjugate Vaccines Revenue (2017-2028) & (US$ Million)
    Figure 64. Thailand Conjugate Vaccines Revenue (2017-2028) & (US$ Million)
    Figure 65. Malaysia Conjugate Vaccines Revenue (2017-2028) & (US$ Million)
    Figure 66. Philippines Conjugate Vaccines Revenue (2017-2028) & (US$ Million)
    Figure 67. Latin America Conjugate Vaccines Sales Market Share by Type (2017-2028)
    Figure 68. Latin America Conjugate Vaccines Revenue Market Share by Type (2017-2028)
    Figure 69. Latin America Conjugate Vaccines Sales Market Share by Application (2017-2028)
    Figure 70. Latin America Conjugate Vaccines Revenue Market Share by Application (2017-2028)
    Figure 71. Latin America Conjugate Vaccines Sales Share by Country (2017-2028)
    Figure 72. Latin America Conjugate Vaccines Revenue Share by Country (2017-2028)
    Figure 73. Mexico Conjugate Vaccines Revenue (2017-2028) & (US$ Million)
    Figure 74. Brazil Conjugate Vaccines Revenue (2017-2028) & (US$ Million)
    Figure 75. Argentina Conjugate Vaccines Revenue (2017-2028) & (US$ Million)
    Figure 76. Middle East and Africa Conjugate Vaccines Sales Market Share by Type (2017-2028)
    Figure 77. Middle East and Africa Conjugate Vaccines Revenue Market Share by Type (2017-2028)
    Figure 78. Middle East and Africa Conjugate Vaccines Sales Market Share by Application (2017-2028)
    Figure 79. Middle East and Africa Conjugate Vaccines Revenue Market Share by Application (2017-2028)
    Figure 80. Middle East and Africa Conjugate Vaccines Sales Share by Country (2017-2028)
    Figure 81. Middle East and Africa Conjugate Vaccines Revenue Share by Country (2017-2028)
    Figure 82. Turkey Conjugate Vaccines Revenue (2017-2028) & (US$ Million)
    Figure 83. Saudi Arabia Conjugate Vaccines Revenue (2017-2028) & (US$ Million)
    Figure 84. U.A.E Conjugate Vaccines Revenue (2017-2028) & (US$ Million)
    Figure 85. Conjugate Vaccines Value Chain
    Figure 86. Conjugate Vaccines Production Process
    Figure 87. Channels of Distribution
    Figure 88. Distributors Profiles
    Figure 89. Bottom-up and Top-down Approaches for This Report
    Figure 90. Data Triangulation
    Figure 91. Key Executives Interviewed